Create a PowerPoint presentation on psoriasis covering overview, epidemiology, pathophysiology, clinical presentation, assessment, management, and patient education.

Psoriasis PowerPoint Presentation Guide

For a comprehensive psoriasis presentation, structure your content around the chronic, immune-mediated nature of this disease affecting approximately 2-3% of the global population, emphasizing that while no cure exists, treatment aims to induce remission and make disease tolerable for patients 1, 2.

Slide 1: Overview & Definition

Psoriasis is a genetic, systemic, inflammatory chronic disorder characterized by scaly, erythematous patches, papules, and plaques that are often pruritic and significantly impact quality of life 3.

• Multisystem disease with predominantly skin and joint manifestations
• Chronic disease that waxes and wanes throughout lifetime
• Few spontaneous remissions occur
• Associated with significant psychosocial disability including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation 3

Slide 2: Epidemiology

• Affects approximately 2% of the population globally 3
• 1.52% prevalence in UK population 4
• Estimated 60 million people affected worldwide 4
• Can affect all ages, with guttate variant common in individuals younger than 30 years 3
• No gender predominance

Slide 3: Pathophysiology

Psoriasis involves dysregulated immune mechanisms centered on the IL-23-T helper 17 axis, leading to chronic inflammation and keratinocyte hyperproliferation 2.

Key pathogenic mechanisms:

• Genetic component: HLA-Cw6 allele (PSORS1) is the major susceptibility gene, particularly in early-onset disease 3, 2
• Additional susceptibility loci: IL23A, IL12B, IL17RA 2
• Immune dysregulation with intralesional T cells, dermal dendritic cells, and neutrophils 3
• Elevated TNF-α, interferon-γ, and IL-12/23-dependent genes 3
• Environmental triggers: drugs, skin trauma (Koebner's phenomenon), infection, stress 3

Slide 4: Clinical Presentation - Subtypes

Diagnosis is clinical; laboratory investigations are rarely helpful 1.

Chronic Plaque Psoriasis (Most Common)

• Well-demarcated, erythematous plaques with silvery scale
• Typically on extensor surfaces, scalp, trunk

Guttate Psoriasis

• Dew-drop-like, 1-10mm salmon-pink papules with fine scale
• Primarily trunk and proximal extremities
• Common in individuals <30 years 3

Inverse Psoriasis

• Erythematous plaques with minimal scale in skin folds
• Axillary, genital, perineal, intergluteal, inframammary areas 3

Pustular Psoriasis

• Generalized (von Zumbusch variant): widespread pustules on erythematous background with fever and toxicity
• Localized: palms and soles involvement 3

Erythrodermic Psoriasis

• Generalized erythema covering nearly entire body surface area
• Risk of hypothermia, dehydration, fever, malaise 3

Nail Psoriasis

• Pitting, onycholysis, subungual hyperkeratosis, oil-drop sign
• Occurs in ~50% of fingernails, 35% of toenails
• Up to 90% of psoriatic arthritis patients have nail changes 3

Slide 5: Assessment of Severity

Assessment must include two components: patient's perception of disability ("need for treatment") and objective assessment of extent and severity 1.

Objective measures:

• Body surface area (BSA) affected
• Body mapping
• Psoriasis Area and Severity Index (PASI)
• Quality of life impact (may be large even with small areas, e.g., palms/soles) 3

Slide 6: Associated Comorbidities

Psoriasis is associated with increased morbidity and mortality through multiple comorbidities 3, 2.

Critical comorbidities to screen for:

• Psoriatic arthritis: affects ~25% of patients 5
• Cardiovascular disease: increased risk requiring proactive risk reduction 2
• Metabolic syndrome: obesity, diabetes, hypertension 3, 6
• Non-alcoholic fatty liver disease (NAFLD): elevated rates, particularly with systemic therapy 6
• Inflammatory bowel disease: 3.8-7.5 times greater incidence 3
• Psychiatric disorders: depression, anxiety requiring screening 2
• Increased overall mortality in severe psoriasis 3

Slide 7: Drugs That Worsen Psoriasis

Critical pitfall: Certain medications can precipitate severe, even life-threatening deterioration 1.

• High risk: Lithium, chloroquine, mepacrine (can cause severe deterioration)
• Moderate risk: Beta-blockers, NSAIDs, alcohol
• Avoid these agents when possible in psoriasis patients

Slide 8: Management Algorithm - Mild Disease

Most patients with stable chronic plaque psoriasis and guttate psoriasis should be managed by general practitioners 1.

First-line approach:

1. Patient preference assessment - option of no active treatment or simple emollient is appropriate 1
2. If active treatment desired: Topical agents of proven efficacy
   • Coal tar: Start 0.5-1.0% crude coal tar in petroleum jelly, increase to maximum 10% 1
   • Dithranol: Start 0.1-0.25%, increase in doubling concentrations; caution on face, flexures, genitalia 1
   • Topical corticosteroids under carefully monitored conditions 1

Topical corticosteroid guidelines 1:

• Regular clinical review required
• No unsupervised repeat prescriptions
• Maximum 100g of moderately potent preparation per month
• Periods each year when alternative treatment employed
• Very potent or potent preparations only under dermatological supervision

Newer topical options 2:

• Vitamin D analogues
• Topical calcineurin inhibitors
• PDE4 inhibitors
• Aryl hydrocarbon receptor agonists

Slide 9: Management Algorithm - Moderate-to-Severe Disease

Patients with severe psoriasis requiring systemic agents should be under continuing supervision of a consultant dermatologist due to potential toxicity 1.

Phototherapy:

• Narrowband UVB (NB-UVB)
• PUVA (psoralen and UVA)
• Not available to many due to geographical/logistical constraints 5

Oral Systemic Therapies 2, 4:

• Methotrexate: Primary systemic option for many patients 7
• Ciclosporin
• Acitretin
• Apremilast (PDE4 inhibitor)
• Deucravacitinib (Tyk2 inhibitor)
• Dimethyl fumarate

Biologic Therapies (for severe disease) 5, 3, 2:

Biologic therapies utilize molecules designed to block specific molecular steps in psoriasis pathogenesis and are now well-established, licensed options for severe disease 5.

Available biologics:

• TNF-α inhibitors: Infliximab, adalimumab, etanercept
• IL-17 inhibitors: Highly effective for cutaneous and systemic inflammation
• IL-23 inhibitors: Ustekinumab and newer agents
• IL-12/23 inhibitors

NICE has approved multiple biologic therapies for severe chronic plaque psoriasis, though funding remains a significant obstacle in ~40% of UK units 5.

Slide 10: Management of Psoriatic Arthritis

For moderate-to-severe psoriatic arthritis without contraindications, initiate methotrexate therapy; if minimal improvement after 12-16 weeks with appropriate dose escalation, add or switch to TNF-α inhibitor 8.

All TNF-α inhibitors are equally reasonable choices for psoriatic arthritis 8.

Slide 11: Monitoring and Safety

Baseline screening for biologics 9:

• Complete blood count
• Complete metabolic profile
• TB testing (PPD or Quantiferon Gold)
• Hepatitis B and C serology
• Chest radiograph for positive TB test
• HIV testing based on risk factors

Ongoing monitoring 9:

• Periodic history and physical examination
• Screen for nonmelanoma skin cancer
• Yearly TB testing in high-risk patients
• Annual chest radiograph at discretion
• Hepatitis screening
• Infection evaluation

Surgery considerations 9:

• Continue biologics through low-risk procedures
• For moderate/high-risk procedures: discontinue 3-4 half-lives before and until 1-2 weeks after surgery

Vaccination 9:

• Inactivated vaccines: safe during biologic therapy
• Live vaccines: discontinue biologics before administration (timing varies by expert opinion)

Slide 12: Patient Education

Patient education is essential to optimizing treatment for all disease severity categories 8, 6, 9.

Key educational components:

• Disease etiology: Genetic, immune-mediated, chronic nature
• Comorbidity awareness: Screen for cardiovascular disease, diabetes, metabolic syndrome, depression
• Treatment options: Benefits, risks, alternatives of each modality
• Lifestyle modifications: Weight management, cardiovascular risk reduction
• Shared decision-making: Patient input into treatment plan improves adherence

Resources to provide:

• National Psoriasis Foundation (www.psoriasis.org)
• International Federation of Psoriasis Associations (www.IFPA-pso.org)
• American Academy of Dermatology (www.aad.org)
• Patient pamphlets and trusted internet resources 8, 6

Critical counseling points:

• Establish primary care relationship: Dermatologists may be sole physician for younger patients; ensure comprehensive comorbidity management 8
• Psoriasis nurse specialists: Valuable for counseling and education 8
• Holistic approach: Address physical, psychological, and social well-being 6, 10
• Early intervention: Stratified medicine approach with regular review as presentation and needs change over time 10

Slide 13: Special Populations

Pediatric considerations:

• Children affected by psoriasis and comorbidities
• Specific guidelines exist for pediatric population 6

Pregnancy planning:

• Specific treatment modifications required
• Consultation with specialists recommended 7

Patients with specific comorbidities:

• Tailor treatment to individual risk factors
• Multidisciplinary care approach essential 6, 2

Slide 14: Future Directions

Current research focuses on precision medicine approaches to enhance treatment durability and improve quality of life 2.

Emerging therapies:

• Additional Tyk2 pathway inhibitors
• IL-23 receptor inhibitors
• Novel IL-17 and TNF inhibitors
• Epigenetic modulators
• Stem cell therapies 11

Research priorities 8:

• Comparative effectiveness studies (currently understudied)
• Long-term safety and efficacy data
• Genotype-phenotype correlations
• Impact of treatment on preventing comorbidities
• Health disparities in psoriasis care